These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33854188)

  • 1. Performance of a cardiac lipid panel compared to four prognostic scores in chronic heart failure.
    McGranaghan P; Saxena A; Düngen HD; Rubens M; Appunni S; Salami J; Veledar E; Lacour P; Blaschke F; Obradovic D; Loncar G; Tahirovic E; Edelmann F; Pieske B; Trippel TD
    Sci Rep; 2021 Apr; 11(1):8164. PubMed ID: 33854188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of the MAGGIC (Meta-Analysis Global Group in Chronic Heart Failure) heart failure risk score and the effect of adding natriuretic peptide for predicting mortality after discharge in hospitalized patients with heart failure.
    Khanam SS; Choi E; Son JW; Lee JW; Youn YJ; Yoon J; Lee SH; Kim JY; Ahn SG; Ahn MS; Kang SM; Baek SH; Jeon ES; Kim JJ; Cho MC; Chae SC; Oh BH; Choi DJ; Yoo BS
    PLoS One; 2018; 13(11):e0206380. PubMed ID: 30485284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incremental prognostic value of a novel metabolite-based biomarker score in congestive heart failure patients.
    McGranaghan P; Düngen HD; Saxena A; Rubens M; Salami J; Radenkovic J; Bach D; Apostolovic S; Loncar G; Zdravkovic M; Tahirovic E; Veskovic J; Störk S; Veledar E; Pieske B; Edelmann F; Trippel TD
    ESC Heart Fail; 2020 Oct; 7(5):3029-3039. PubMed ID: 32860352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Head-to-head comparison of contemporary heart failure risk scores.
    Codina P; Lupón J; Borrellas A; Spitaleri G; Cediel G; Domingo M; Simpson J; Levy WC; Santiago-Vacas E; Zamora E; Buchaca D; Subirana I; Santesmases J; Diez-Quevedo C; Troya MI; Boldo M; Altmir S; Alonso N; González B; Rivas C; Nuñez J; McMurray J; Bayes-Genis A
    Eur J Heart Fail; 2021 Dec; 23(12):2035-2044. PubMed ID: 34558158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-terminal fraction of pro-B-type natriuretic peptide versus clinical risk scores for prognostic stratification in chronic systolic heart failure.
    Arzilli C; Aimo A; Vergaro G; Ripoli A; Senni M; Emdin M; Passino C
    Eur J Prev Cardiol; 2018 May; 25(8):889-895. PubMed ID: 29569494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble ST2, BCN-Bio-HF calculator and MAGGIC-HF score in long-term risk prediction after an urgent visit for heart failure.
    Pérez-Sanz TM; Gómez-Salvador I; Codina P; Calvo Antón B; de la Torre Carpente MM; Redondo Bermejo B; Tapia Ballesteros C
    Heart Vessels; 2024 Mar; 39(3):216-225. PubMed ID: 37872307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes of natriuretic peptides predict hospital admissions in patients with chronic heart failure: a meta-analysis.
    Savarese G; Musella F; D'Amore C; Vassallo E; Losco T; Gambardella F; Cecere M; Petraglia L; Pagano G; Fimiani L; Rengo G; Leosco D; Trimarco B; Perrone-Filardi P
    JACC Heart Fail; 2014 Apr; 2(2):148-58. PubMed ID: 24720923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meta-Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score: Validation of a Simple Tool for the Prediction of Morbidity and Mortality in Heart Failure With Preserved Ejection Fraction.
    Rich JD; Burns J; Freed BH; Maurer MS; Burkhoff D; Shah SJ
    J Am Heart Assoc; 2018 Oct; 7(20):e009594. PubMed ID: 30371285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Performance of Prognostic Risk Scores in Elderly Chinese Patients with Heart Failure.
    Cheng Y; Chai K; Zhu W; Wan Y; Liang Y; Du M; Li Y; Sun N; Yang J; Wang H
    Clin Interv Aging; 2021; 16():1669-1677. PubMed ID: 34556979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.
    Masson S; Latini R; Anand IS; Vago T; Angelici L; Barlera S; Missov ED; Clerico A; Tognoni G; Cohn JN;
    Clin Chem; 2006 Aug; 52(8):1528-38. PubMed ID: 16777915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of clinical effect and treatment quality of immediate-release carvedilol-IR versus SLOW release carvedilol-SR in Heart Failure patients (SLOW-HF): study protocol for a randomized controlled trial.
    Choi DJ; Park CS; Park JJ; Lee HY; Kang SM; Yoo BS; Jeon ES; Hong SK; Shin JH; Kim MA; Park DG; Kim EJ; Hong SJ; Kim SY; Kim JJ
    Trials; 2018 Feb; 19(1):103. PubMed ID: 29433525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does NT-proBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker?
    Li N; Li Y; Wang F; Jiang W; Huang J; Xu Z; Hua L; Hua C; Huang Y; Wu Y; Li F
    Clin Cardiol; 2007 Sep; 30(9):469-74. PubMed ID: 17803204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisoprolol and heart failure: new frontiers.
    Chopra HK
    Indian Heart J; 2010; 62(1):7-12. PubMed ID: 21180027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beneficial Effect on Surrogate Markers of Heart Failure with Bisoprolol Up-Titration to Recommended Targets in Korean Patients with Heart Failure and Left Ventricular Systolic Dysfunction.
    Han SW; Choi SW; Ryu KH; Kim HJ; Kim SH; Shim WJ; Cha TJ; Choi DJ; Kim YJ; Yoo BS; Kim JH; Hwang KK; Jeon H; Shin MS
    Cardiovasc Ther; 2016 Jun; 34(3):172-9. PubMed ID: 27003232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial.
    Jabbour A; Macdonald PS; Keogh AM; Kotlyar E; Mellemkjaer S; Coleman CF; Elsik M; Krum H; Hayward CS
    J Am Coll Cardiol; 2010 Apr; 55(17):1780-7. PubMed ID: 20413026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic utility of the Seattle Heart Failure Score and amino terminal pro B-type natriuretic peptide in varying stages of systolic heart failure.
    Adlbrecht C; Hülsmann M; Neuhold S; Strunk G; Pacher R
    J Heart Lung Transplant; 2013 May; 32(5):533-8. PubMed ID: 23453573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.
    Bo X; Zhang Y; Liu Y; Kharbuja N; Chen L
    ESC Heart Fail; 2023 Feb; 10(1):502-517. PubMed ID: 36325751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry.
    Canepa M; Fonseca C; Chioncel O; Laroche C; Crespo-Leiro MG; Coats AJS; Mebazaa A; Piepoli MF; Tavazzi L; Maggioni AP;
    JACC Heart Fail; 2018 Jun; 6(6):452-462. PubMed ID: 29852929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice].
    Ageev FT; Zhubrina ES; Ovchinnikov AG; Seredenina EM
    Kardiologiia; 2010; 50(6):41-7. PubMed ID: 20659026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.